- Home
- PKE vs ZNTL Comparison
PKE vs ZNTL Comparison
Compare PKE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ZNTL
- Stock Information
- Founded
- PKE 1954
- ZNTL 2014
- Country
- PKE United States
- ZNTL United States
- Employees
- PKE N/A
- ZNTL N/A
- Industry
- PKE Military/Government/Technical
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ZNTL Health Care
- Exchange
- PKE Nasdaq
- ZNTL Nasdaq
- Market Cap
- PKE 277.5M
- ZNTL 238.2M
- IPO Year
- PKE N/A
- ZNTL 2020
- Fundamental
- Price
- PKE $14.41
- ZNTL $3.12
- Analyst Decision
- PKE
- ZNTL Buy
- Analyst Count
- PKE 0
- ZNTL 7
- Target Price
- PKE N/A
- ZNTL $10.86
- AVG Volume (30 Days)
- PKE 87.5K
- ZNTL 1.2M
- Earning Date
- PKE 10-15-2024
- ZNTL 11-04-2024
- Dividend Yield
- PKE 3.48%
- ZNTL N/A
- EPS Growth
- PKE N/A
- ZNTL N/A
- EPS
- PKE 0.34
- ZNTL N/A
- Revenue
- PKE $58,651,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- PKE N/A
- ZNTL N/A
- Revenue Next Year
- PKE N/A
- ZNTL N/A
- P/E Ratio
- PKE $42.64
- ZNTL N/A
- Revenue Growth
- PKE 5.81
- ZNTL N/A
- 52 Week Low
- PKE $11.96
- ZNTL $2.83
- 52 Week High
- PKE $16.96
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- PKE 62.75
- ZNTL 44.34
- Support Level
- PKE $13.20
- ZNTL $2.92
- Resistance Level
- PKE $15.20
- ZNTL $3.23
- Average True Range (ATR)
- PKE 0.38
- ZNTL 0.17
- MACD
- PKE 0.15
- ZNTL 0.00
- Stochastic Oscillator
- PKE 65.60
- ZNTL 38.33
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.